Free Trial

Aprea Therapeutics (APRE) Competitors

Aprea Therapeutics logo
$1.89 -0.04 (-2.07%)
Closing price 04:00 PM Eastern
Extended Trading
$1.83 -0.06 (-3.39%)
As of 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

APRE vs. CGTX, KALA, BDRX, AKTX, TELO, COEP, HYPD, OKUR, MAAQ, and KZR

Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Cognition Therapeutics (CGTX), KALA BIO (KALA), Biodexa Pharmaceuticals (BDRX), Akari Therapeutics (AKTX), Telomir Pharmaceuticals (TELO), Coeptis Therapeutics (COEP), Hyperion DeFi (HYPD), OnKure Therapeutics (OKUR), Mana Capital Acquisition (MAAQ), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry.

Aprea Therapeutics vs. Its Competitors

Aprea Therapeutics (NASDAQ:APRE) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 13.6% of Aprea Therapeutics shares are held by insiders. Comparatively, 14.4% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cognition Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,095.02%. Aprea Therapeutics' return on equity of -68.39% beat Cognition Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aprea Therapeutics-1,095.02% -68.39% -55.74%
Cognition Therapeutics N/A -194.42%-115.14%

Aprea Therapeutics has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aprea Therapeutics$1.50M6.97-$12.96M-$2.37-0.80
Cognition TherapeuticsN/AN/A-$33.97M-$0.74-1.14

In the previous week, Cognition Therapeutics had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 2 mentions for Cognition Therapeutics and 1 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.89 beat Cognition Therapeutics' score of 0.93 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aprea Therapeutics Very Positive
Cognition Therapeutics Positive

Aprea Therapeutics currently has a consensus price target of $15.50, suggesting a potential upside of 720.11%. Cognition Therapeutics has a consensus price target of $2.83, suggesting a potential upside of 237.30%. Given Aprea Therapeutics' higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than Cognition Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aprea Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cognition Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

Aprea Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Summary

Aprea Therapeutics beats Cognition Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APRE vs. The Competition

MetricAprea TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$10.68M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-0.8021.0428.0720.05
Price / Sales6.97284.46448.5799.42
Price / CashN/A42.7636.2258.56
Price / Book0.538.378.665.87
Net Income-$12.96M-$55.19M$3.25B$258.55M
7 Day Performance13.86%5.89%4.20%2.23%
1 Month Performance5.00%17.63%10.82%12.76%
1 Year Performance-51.04%5.09%34.70%19.36%

Aprea Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APRE
Aprea Therapeutics
2.922 of 5 stars
$1.89
-2.1%
$15.50
+720.1%
-50.1%$10.68M$1.50M-0.807Positive News
CGTX
Cognition Therapeutics
2.7768 of 5 stars
$0.61
+6.6%
$2.83
+368.3%
-53.2%$37.51MN/A-0.8220
KALA
KALA BIO
3.9708 of 5 stars
$5.70
-2.6%
$13.00
+128.1%
-0.3%$36.77M$3.89M-0.6930
BDRX
Biodexa Pharmaceuticals
0.2905 of 5 stars
$0.98
+12.1%
N/AN/A$35.81M$470K0.0020Positive News
High Trading Volume
AKTX
Akari Therapeutics
2.6588 of 5 stars
$1.11
-1.7%
N/A-71.9%$35.75MN/A0.009
TELO
Telomir Pharmaceuticals
2.9162 of 5 stars
$1.17
+0.9%
$15.00
+1,182.1%
-43.7%$34.82MN/A-2.791News Coverage
Gap Down
COEP
Coeptis Therapeutics
0.6828 of 5 stars
$9.90
+4.5%
N/A+117.3%$34.79M$62.87K-1.712Positive News
Gap Up
HYPD
Hyperion DeFi
1.132 of 5 stars
$12.03
-9.1%
$2.00
-83.4%
-92.8%$34.65M$60K-0.2140Positive News
Gap Up
OKUR
OnKure Therapeutics
3.4043 of 5 stars
$2.50
flat
$32.33
+1,193.3%
N/A$33.78MN/A-0.48N/APositive News
MAAQ
Mana Capital Acquisition
N/A$4.15
-3.3%
N/A+812.7%$33.72MN/A0.001Gap Up
KZR
Kezar Life Sciences
4.1969 of 5 stars
$4.58
+1.6%
$39.50
+762.4%
-32.4%$33.48M$7M-0.4260

Related Companies and Tools


This page (NASDAQ:APRE) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners